News | March 17, 2024
Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
Both organisations enter into a long- term collaboration to expand patient access in India
Both organisations enter into a long- term collaboration to expand patient access in India
Total transaction value of the divestment is Rs. 3,660 million
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
Eris Lifesciences has reported total income of Rs.1220.57 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)